The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
Open accessAbstract
Recent studies suggest that tumor-associated CD11b + Gr1 + myeloid cells contribute to refractoriness to antiangiogenic therapy with an anti-VEGF-A antibody. However, the mechanisms of peripheral mobilization and tumor-homing of CD11b + Gr1 + cells are unclear. Here, we show that, compared with other cytokines [granulocyte-macrophage colony stimulating factor (GM-CSF), stromal derived factor 1α, and placenta growth factor], G-CSF and the G-CSF-induced Bv8 protein have preferential expression in refractory tumors. Treatment of refractory tumors with the combination of anti-VEGF and anti-G-CSF (or anti-Bv8) reduced tumor growth compared with anti-VEGF-A monotherapy. Anti-G-CSF treatment dramatically suppressed circulating or tumor-associated CD11b + Gr1 + cells, reduced Bv8 levels, and affected the tumor vasculature. Conversely, G-CSF delivery to animals bearing anti-VEGF sensitive tumors resulted in reduced responsiveness to anti-VEGF-A treatment through induction of Bv8-dependent angiogenesis. We conclude that, at least in the models examined, G-CSF expression by tumor or stromal cells is a determinant of refractoriness to anti-VEGF-A treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Food and Drug Administration (FDA) for cancer therapy, in combination with cytotoxic chemotherapy (5, 6).”
BackgroundSelf-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Lieschke, G., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K., Basu, S., Zhan, Y., & Dunn, A. (1994) · Blood · doi:10.1182/blood.v84.6.1737.1737 · Cited by 962
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 5×
“In all experiments, tumor volumes were measured by using a caliper, as described (14).”
BackgroundMethodSelf-citationAnti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus
Cheng, M. Y., Bullock, C. M., Li, C., Lee, A. G., Bermak, J. C., Belluzzi, J., Weaver, D. R., Leslie, F. M., & Zhou, Q.-Y. (2002) · Nature · doi:10.1038/417405a · Cited by 715
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Self-citationCrawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Self-citationTumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
De Palma, M., Venneri, M. A., Roca, C., & Naldini, L. (2003) · Nature Medicine · doi:10.1038/nm871 · Cited by 549
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Self-citationRole of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
Self-citationBasu, S., Hodgson, G., Katz, M., & Dunn, A. R. (2002) · Blood · doi:10.1182/blood.v100.3.854 · Cited by 316
Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications
De Palma, M., Murdoch, C., Venneri, M. A., Naldini, L., & Lewis, C. E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.004 · Cited by 287
Matsumoto, S.-I., Yamazaki, C., Masumoto, K.-H., Nagano, M., Naito, M., Soga, T., Hiyama, H., Matsumoto, M., Takasaki, J., Kamohara, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508881103 · Cited by 281 · cited 1×
“Further experiments revealed that CD11b Gr1 cells produce several angiogenic factors, including Bv8, a secreted protein previously characterized as a mitogen for specific endothelial cell type, as a growth factor for hematopoietic progenitors (15, 16), and as a neuromodulator (17, 18).”
BackgroundHamilton, J. A., & Anderson, G. P. (2004) · Growth Factors · doi:10.1080/08977190412331279881 · Cited by 224
Lyman, G. H., Kuderer, N. M., & Djulbegovic, B. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01036-7 · Cited by 221
LeCouter, J., Zlot, C., Tejada, M., Peale, F., & Ferrara, N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407697101 · Cited by 219
Self-citationLeCouter, J., Lin, R., Tejada, M., Frantz, G., Peale, F., Hillan, K. J., & Ferrara, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337667100 · Cited by 201
Self-citationNatori, T., Sata, M., Washida, M., Hirata, Y., Nagai, R., & Makuuchi, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02335-5 · Cited by 200
Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia
Lee, S.-T., Chu, K., Jung, K.-H., Ko, S.-Y., Kim, E.-H., Sinn, D. I., Lee, Y. S., Lo, E. H., Kim, M., & Roh, J. K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.07.076 · Cited by 186
DC ablation in mice: promises, pitfalls, and challenges
Bennett, C. L., & Clausen, B. E. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.08.011 · Cited by 181
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
Self-citationRole of myeloid cells in tumor angiogenesis and growth
Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.06.003 · Cited by 167
Self-citationIn vivo activation of JAK2/STAT‐3 pathway during angiogenesis induced by GM‐CSF
Valdembri, D., Serini, G., Vacca, A., Ribatti, D., & Bussolino, F. (2002) · The FASEB Journal · doi:10.1096/fj.01-0633fje · Cited by 144
Ripa, R. S., Wang, Y., Jørgensen, E., Johnsen, H. E., Hesse, B., & Kastrup, J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl117 · Cited by 144
Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck
Ninck, S., Reisser, C., Dyckhoff, G., Helmke, B. M., Bauer, H., & Herold‐Mende, C. C. (2003) · International Journal of Cancer · doi:10.1002/ijc.11188 · Cited by 141
Rapoport, A. P., Abboud, C. N., & DiPersio, J. F. (1992) · Blood Reviews · doi:10.1016/0268-960x(92)90007-d · Cited by 136
Mueller, M. M., Peter, W., Mappes, M., Huelsen, A., Steinbauer, H., Boukamp, P., Vaccariello, M. A., Garlick, J. A., & Fusenig, N. E. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62541-2 · Cited by 133
Okazaki, T., Ebihara, S., Asada, M., Kanda, A., Sasaki, H., & Yamaya, M. (2005) · International Immunology · doi:10.1093/intimm/dxh334 · Cited by 104
HIRASAWA, K., Kitamura, T., Oka, T., & Matsushita, H. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)65104-x · Cited by 56
Lung Large Cell Carcinoma Producing Granulocyte-Colony-Stimulating Factor
Hasegawa, S., Suda, T., Negi, K., & Hattori, Y. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.04.049 · Cited by 24
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Pre-metastatic niches: organ-specific homes for metastases
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Metadata
- Authors
- Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-04-21
- Volume
- 106
- Issue
- 16
- Pages
- 6742-6747
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2139731402
- Cited by
- 471
- References
- 45
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.